BioCentury | Mar 31, 2008
Clinical News

NRX4204: Phase I started

...NuRx (formerly Quest Group International Inc. ) began a Phase I trial of oral NRX4204. The company received exclusive...
BioCentury | May 21, 2007
Company News

Quest Group board of directors update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Hired: Harin Padma-Nathan as CEO, while remaining CSO of Insyght Interactive Inc. WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group scientific advisory board update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Appointed: Parkash Gill, professor of medicine at the University of Southern California's Keck School of Medicine, as chairman WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group, Vitae deal

...Phase I testing to treat cancer by early next year. Financial terms were not disclosed. Quest Group International Inc....
BioCentury | May 19, 2007
Financial News

Quest Group raises $20M, acquires cancer compounds

Quest Group (QSTG) raised $20 million in a private placement. The number of shares and deal price were not disclosed. Hunter World Markets was placement agent. Quest also said that it licensed from Vitae (Fort...
Items per page:
1 - 5 of 5
BioCentury | Mar 31, 2008
Clinical News

NRX4204: Phase I started

...NuRx (formerly Quest Group International Inc. ) began a Phase I trial of oral NRX4204. The company received exclusive...
BioCentury | May 21, 2007
Company News

Quest Group board of directors update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Hired: Harin Padma-Nathan as CEO, while remaining CSO of Insyght Interactive Inc. WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group scientific advisory board update

Quest Group International Inc. (QSTG), Spanish Fork, Utah Business: Nutraceuticals, Cancer Appointed: Parkash Gill, professor of medicine at the University of Southern California's Keck School of Medicine, as chairman WIR Staff cancer...
BioCentury | May 21, 2007
Company News

Quest Group, Vitae deal

...Phase I testing to treat cancer by early next year. Financial terms were not disclosed. Quest Group International Inc....
BioCentury | May 19, 2007
Financial News

Quest Group raises $20M, acquires cancer compounds

Quest Group (QSTG) raised $20 million in a private placement. The number of shares and deal price were not disclosed. Hunter World Markets was placement agent. Quest also said that it licensed from Vitae (Fort...
Items per page:
1 - 5 of 5